Cytrx cancer drug shows promise in mid-stage study

(Reuters) - Cytrx Corp said interim data showed its experimental cancer drug was effective in a mid-stage study to treat patients with a deadly form of brain cancer. The drug, aldoxorubicin, prevented the disease from progressing and shrank tumors, the company said. The U.S. Food and Drug Administration had placed a hold on enrolling new patients in clinical trials of aldoxorubicin in November, after a patient died. (Reporting by Rosmi Shaji in Bengaluru; Editing by Savio D'Souza)



via Health News Headlines - Yahoo News http://ift.tt/1Dejaao